{"id":50441,"date":"2022-11-03T14:02:18","date_gmt":"2022-11-03T13:02:18","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/syros-pharmaceuticals-to-present-initial-data-from-select-aml-1-phase-2-trial-at-64th-ash-annual-meeting\/"},"modified":"2022-11-03T14:02:18","modified_gmt":"2022-11-03T13:02:18","slug":"syros-pharmaceuticals-to-present-initial-data-from-select-aml-1-phase-2-trial-at-64th-ash-annual-meeting","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/syros-pharmaceuticals-to-present-initial-data-from-select-aml-1-phase-2-trial-at-64th-ash-annual-meeting\/","title":{"rendered":"Syros Pharmaceuticals to Present Initial Data from SELECT-AML-1 Phase 2 Trial at 64th ASH Annual Meeting"},"content":{"rendered":"
\n

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will present initial data from the safety lead-in portion of its ongoing SELECT-AML-1 Phase 2 clinical trial at the 64th<\/sup> American Society of Hematology (ASH) Annual Meeting, taking place December 10-13, 2022 in New Orleans, LA. The SELECT-AML-1 trial is evaluating tamibarotene, Syros\u2019 first-in-class selective retinoic acid receptor alpha (RAR\u03b1) agonist, in combination with venetoclax and azacitidine in patients with newly diagnosed, unfit acute myeloid leukemia (AML) with RARA<\/i> gene overexpression.\n<\/p>\n

<\/a><\/p>\n

\nDetails of the poster presentation are as follows:\n<\/p>\n

\nPresentation Title:<\/b> Initial Results from SELECT-AML-1, a Phase 2 study of Tamibarotene in Combination with Venetoclax and Azacitidine in RARA-positive Newly Diagnosed AML Patients Ineligible for Standard Induction Chemotherapy
\n
Session Title: <\/b>616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster I
\n
Session Date & Time: <\/b>Saturday, December 10, 2022, 5:30 \u2013 7:30 pm CT (6:30 \u2013 8:30 pm ET)
\n
Location: <\/b>Ernest N. Morial Convention Center, Hall D
\n
Publication Number: <\/b>1444\n<\/p>\n

\nThe abstract is now available online on the ASH Conference website at:
\n
https:\/\/www.hematology.org\/meetings\/annual-meeting<\/a>.\n<\/p>\n

\nAbout Syros Pharmaceuticals<\/b>\n<\/p>\n

\nSyros is redefining the power of small molecules to control the expression of genes. Based on its unique ability to elucidate regulatory regions of the genome, Syros aims to develop medicines that provide a profound benefit for patients with diseases that have eluded other genomics-based approaches. Syros is advancing a robust clinical-stage pipeline, including: tamibarotene, a first-in-class oral selective RAR\u03b1 agonist in patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia with RARA<\/i> gene overexpression; SY-2101, a novel oral form of arsenic trioxide in patients with acute promyelocytic leukemia; and SY-5609, a highly selective and potent oral CDK7 inhibitor in patients with select solid tumors. Syros also has multiple preclinical and discovery programs in oncology and monogenic diseases. For more information, visit www.syros.com<\/a> and follow us on Twitter (@SyrosPharma<\/a>) and LinkedIn<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nSyros<\/b>
Karen Hunady
\n
Director of Corporate Communications & Investor Relations
\n
1-857-327-7321
\n
khunady@syros.com<\/a><\/p>\n

Media<\/b>
Brittany Leigh, Ph.D.
\n
LifeSci Communications, LLC
\n
+1-813-767-7801
\n
bleigh@lifescicomms.com<\/a><\/p>\n

Investor<\/b>
Hannah Deresiewicz
\n
Stern Investor Relations, Inc.
\n
212-362-1200
\n
hannah.deresiewicz@sternir.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will present initial data from the safety lead-in portion of its ongoing SELECT-AML-1 Phase 2 clinical trial at the 64th American Society of Hematology (ASH) Annual Meeting, taking place December 10-13, 2022 in … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-50441","6":"format-standard","7":"category-industry"},"yoast_head":"\nSyros Pharmaceuticals to Present Initial Data from SELECT-AML-1 Phase 2 Trial at 64th ASH Annual Meeting - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/syros-pharmaceuticals-to-present-initial-data-from-select-aml-1-phase-2-trial-at-64th-ash-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Syros Pharmaceuticals to Present Initial Data from SELECT-AML-1 Phase 2 Trial at 64th ASH Annual Meeting - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass.–(BUSINESS WIRE)–Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will present initial data from the safety lead-in portion of its ongoing SELECT-AML-1 Phase 2 clinical trial at the 64th American Society of Hematology (ASH) Annual Meeting, taking place December 10-13, 2022 in ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/syros-pharmaceuticals-to-present-initial-data-from-select-aml-1-phase-2-trial-at-64th-ash-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-03T13:02:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221103005107\/en\/1622582\/21\/Syros_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/syros-pharmaceuticals-to-present-initial-data-from-select-aml-1-phase-2-trial-at-64th-ash-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/syros-pharmaceuticals-to-present-initial-data-from-select-aml-1-phase-2-trial-at-64th-ash-annual-meeting\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Syros Pharmaceuticals to Present Initial Data from SELECT-AML-1 Phase 2 Trial at 64th ASH Annual Meeting\",\"datePublished\":\"2022-11-03T13:02:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/syros-pharmaceuticals-to-present-initial-data-from-select-aml-1-phase-2-trial-at-64th-ash-annual-meeting\\\/\"},\"wordCount\":378,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/syros-pharmaceuticals-to-present-initial-data-from-select-aml-1-phase-2-trial-at-64th-ash-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221103005107\\\/en\\\/1622582\\\/21\\\/Syros_Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/syros-pharmaceuticals-to-present-initial-data-from-select-aml-1-phase-2-trial-at-64th-ash-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/syros-pharmaceuticals-to-present-initial-data-from-select-aml-1-phase-2-trial-at-64th-ash-annual-meeting\\\/\",\"name\":\"Syros Pharmaceuticals to Present Initial Data from SELECT-AML-1 Phase 2 Trial at 64th ASH Annual Meeting - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/syros-pharmaceuticals-to-present-initial-data-from-select-aml-1-phase-2-trial-at-64th-ash-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/syros-pharmaceuticals-to-present-initial-data-from-select-aml-1-phase-2-trial-at-64th-ash-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221103005107\\\/en\\\/1622582\\\/21\\\/Syros_Logo.jpg\",\"datePublished\":\"2022-11-03T13:02:18+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/syros-pharmaceuticals-to-present-initial-data-from-select-aml-1-phase-2-trial-at-64th-ash-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/syros-pharmaceuticals-to-present-initial-data-from-select-aml-1-phase-2-trial-at-64th-ash-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/syros-pharmaceuticals-to-present-initial-data-from-select-aml-1-phase-2-trial-at-64th-ash-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221103005107\\\/en\\\/1622582\\\/21\\\/Syros_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221103005107\\\/en\\\/1622582\\\/21\\\/Syros_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/syros-pharmaceuticals-to-present-initial-data-from-select-aml-1-phase-2-trial-at-64th-ash-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Syros Pharmaceuticals to Present Initial Data from SELECT-AML-1 Phase 2 Trial at 64th ASH Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Syros Pharmaceuticals to Present Initial Data from SELECT-AML-1 Phase 2 Trial at 64th ASH Annual Meeting - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/syros-pharmaceuticals-to-present-initial-data-from-select-aml-1-phase-2-trial-at-64th-ash-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Syros Pharmaceuticals to Present Initial Data from SELECT-AML-1 Phase 2 Trial at 64th ASH Annual Meeting - Pharma Trend","og_description":"CAMBRIDGE, Mass.–(BUSINESS WIRE)–Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will present initial data from the safety lead-in portion of its ongoing SELECT-AML-1 Phase 2 clinical trial at the 64th American Society of Hematology (ASH) Annual Meeting, taking place December 10-13, 2022 in ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/syros-pharmaceuticals-to-present-initial-data-from-select-aml-1-phase-2-trial-at-64th-ash-annual-meeting\/","og_site_name":"Pharma Trend","article_published_time":"2022-11-03T13:02:18+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221103005107\/en\/1622582\/21\/Syros_Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/syros-pharmaceuticals-to-present-initial-data-from-select-aml-1-phase-2-trial-at-64th-ash-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/syros-pharmaceuticals-to-present-initial-data-from-select-aml-1-phase-2-trial-at-64th-ash-annual-meeting\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Syros Pharmaceuticals to Present Initial Data from SELECT-AML-1 Phase 2 Trial at 64th ASH Annual Meeting","datePublished":"2022-11-03T13:02:18+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/syros-pharmaceuticals-to-present-initial-data-from-select-aml-1-phase-2-trial-at-64th-ash-annual-meeting\/"},"wordCount":378,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/syros-pharmaceuticals-to-present-initial-data-from-select-aml-1-phase-2-trial-at-64th-ash-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221103005107\/en\/1622582\/21\/Syros_Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/syros-pharmaceuticals-to-present-initial-data-from-select-aml-1-phase-2-trial-at-64th-ash-annual-meeting\/","url":"https:\/\/pharma-trend.com\/en\/syros-pharmaceuticals-to-present-initial-data-from-select-aml-1-phase-2-trial-at-64th-ash-annual-meeting\/","name":"Syros Pharmaceuticals to Present Initial Data from SELECT-AML-1 Phase 2 Trial at 64th ASH Annual Meeting - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/syros-pharmaceuticals-to-present-initial-data-from-select-aml-1-phase-2-trial-at-64th-ash-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/syros-pharmaceuticals-to-present-initial-data-from-select-aml-1-phase-2-trial-at-64th-ash-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221103005107\/en\/1622582\/21\/Syros_Logo.jpg","datePublished":"2022-11-03T13:02:18+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/syros-pharmaceuticals-to-present-initial-data-from-select-aml-1-phase-2-trial-at-64th-ash-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/syros-pharmaceuticals-to-present-initial-data-from-select-aml-1-phase-2-trial-at-64th-ash-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/syros-pharmaceuticals-to-present-initial-data-from-select-aml-1-phase-2-trial-at-64th-ash-annual-meeting\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221103005107\/en\/1622582\/21\/Syros_Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221103005107\/en\/1622582\/21\/Syros_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/syros-pharmaceuticals-to-present-initial-data-from-select-aml-1-phase-2-trial-at-64th-ash-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Syros Pharmaceuticals to Present Initial Data from SELECT-AML-1 Phase 2 Trial at 64th ASH Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50441","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=50441"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50441\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=50441"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=50441"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=50441"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}